Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis

Dauletbaev, 2002, Expression of human β defensin (HBD-1 and HBD-2) mRNA in nasal epithelia of adult cystic fibrosis patients, healthy individuals, and individuals with acute cold, Respiration, 69, 46, 10.1159/000049369 World Health Organization. Global tuberculosis control: WHO report 2011. Geneva: WHO; 2011. Sarkar, 2011, An overview of tuberculosis chemotherapy—a literature review, J Pharm Pharm Sci, 14, 148, 10.18433/J33591 Tabarsi, 2010, Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran, Microb Drug Resist, 16, 81, 10.1089/mdr.2009.0073 Velayati, 2009, Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran, Chest, 136, 420, 10.1378/chest.08-2427 Takiff, 2011, Current prospects for the fluoroquinolones as first-line tuberculosis therapy, Antimicrob Agents Chemother, 55, 5421, 10.1128/AAC.00695-11 Kalita, 2004, Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy, J Infect Dis, 190, 1476, 10.1086/424463 Hale, 2007, Alternative mechanisms of action of cationic antimicrobial peptides on bacteria, Expert Rev Anti Infect Ther, 5, 951, 10.1586/14787210.5.6.951 Hancock, 2006, Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies, Nat Biotechnol, 24, 1551, 10.1038/nbt1267 Afacan, 2012, Therapeutic potential of host defense peptides in antibiotic-resistant infections, Curr Pharm Des, 18, 807, 10.2174/138161212799277617 Rivas-Santiago, 2009, Susceptibility to infectious diseases based on antimicrobial peptide production, Infect Immun, 77, 4690, 10.1128/IAI.01515-08 Yamshchikov, 2010, Vitamin D status and antimicrobial peptide cathelicidin (LL-37) concentrations in patients with active pulmonary tuberculosis, Am J Clin Nutr, 92, 603, 10.3945/ajcn.2010.29411 Rivas-Santiago, 2005, Human β-defensin 2 is expressed and associated with Mycobacterium tuberculosis during infection of human alveolar epithelial cells, Infect Immun, 73, 4505, 10.1128/IAI.73.8.4505-4511.2005 Rivas-Santiago, 2011, Induction of β-defensins by l-isoleucine as novel immunotherapy in experimental murine tuberculosis, Clin Exp Immunol, 164, 80, 10.1111/j.1365-2249.2010.04313.x Rivas-Santiago, 2006, β-Defensin gene expression during the course of experimental tuberculosis infection, J Infect Dis, 194, 697, 10.1086/506454 Liu, 2006, Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response, Science, 311, 1770, 10.1126/science.1123933 Liu, 2007, Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin, J Immunol, 179, 2060, 10.4049/jimmunol.179.4.2060 Hilpert, 2005, High-throughput generation of small antibacterial peptides with improved activity, Nat Biotechnol, 23, 1008, 10.1038/nbt1113 Spindler, 2011, Deciphering the mode of action of the synthetic antimicrobial peptide Bac8c, Antimicrob Agents Chemother, 55, 1706, 10.1128/AAC.01053-10 Dorschner, 2001, Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus, J Invest Dermatol, 117, 91, 10.1046/j.1523-1747.2001.01340.x Zanetti, 2000, Structure and biology of cathelicidins, Adv Exp Med Biol, 479, 203, 10.1007/0-306-46831-X_17 Friedrich, 2000, Antibacterial action of structurally diverse cationic peptides on Gram-positive bacteria, Antimicrob Agents Chemother, 44, 2086, 10.1128/AAC.44.8.2086-2092.2000 Luna-Herrera, 2003, Use of receiver operating characteristic curves to assess the performance of a microdilution assay for determination of drug susceptibility of clinical isolates of Mycobacterium tuberculosis, Eur J Clin Microbiol Infect Dis, 22, 21, 10.1007/s10096-002-0855-5 Rivas-Santiago, 2008, The potential role of lung epithelial cells and β-defensins in experimental latent tuberculosis, Scand J Immunol, 67, 448, 10.1111/j.1365-3083.2008.02088.x Castaneda-Delgado, 2010, Kinetics and cellular sources of cathelicidin during the course of experimental latent tuberculous infection and progressive pulmonary tuberculosis, Clin Exp Immunol, 161, 542, 10.1111/j.1365-2249.2010.04199.x Miyakawa, 1996, In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis, Infect Immun, 64, 926, 10.1128/IAI.64.3.926-932.1996 Nizet, 2001, Innate antimicrobial peptide protects the skin from invasive bacterial infection, Nature, 414, 454, 10.1038/35106587 Zasloff, 2002, Antimicrobial peptides of multicellular organisms, Nature, 415, 389, 10.1038/415389a Sharma, 2001, Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis, Antimicrob Agents Chemother, 45, 639, 10.1128/AAC.45.2.639-640.2001 Achtman, 2012, Effective adjunctive therapy by an innate defense regulatory peptide in a preclinical model of severe malaria, Sci Transl Med, 4, 135ra64, 10.1126/scitranslmed.3003515